Relay Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. (ticker: RLAY) is a United States-based biopharmaceutical company listed on the Nasdaq market. It is a clinical-stage precision-medicine company focused on discovering and developing small-molecule therapies against biologically complex targets, with a primary emphasis on oncology and selected genetic diseases. Founded in 2016, Relay was launched by scientists with deep expertise in structural biology, biophysics, and molecular simulation, with the goal of using protein motion as a basis for more effective drug discovery. The company is headquartered in Cambridge, Massachusetts, in one of the most established biotech clusters in the United States. Relay’s core business is built around its proprietary Dynamo® platform, which combines advanced computational and experimental methods to better map protein dynamics and identify targets that have historically been difficult to drug. The company’s lead asset is zovegalisib (RLY-2608), an investigational allosteric, pan-mutant, isoform-selective PI3Kα inhibitor. That program is being developed mainly in PIK3CA-mutant HR+/HER2- breast cancer, where Relay is testing both doublet and triplet regimens. Beyond that lead oncology asset, the pipeline also includes programs in NRAS-driven solid tumors and Fabry disease, giving the company exposure to both cancer and rare-disease opportunities. From a competitive standpoint, Relay Therapeutics is best viewed as a science-driven biotech with a differentiated discovery engine rather than a commercial-stage company. Its value proposition depends on the quality of its platform, the selectivity and clinical profile of its drug candidates, and the strength of its biomarker-driven development strategy. In a highly competitive environment that includes large pharmaceutical companies and many specialty biotech peers, success will depend on continued clinical execution, regulatory progress, and the ability to show meaningful efficacy with manageable safety and tolerability. Recent developments have been important. In 2026, the U.S. FDA granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for PIK3CA-mutant advanced breast cancer. Relay also reported additional clinical data supporting further development of the zovegalisib plus atirmociclib triplet in frontline metastatic breast cancer, and said its RLY-8161 program has entered clinical development in NRAS-mutant solid tumors. For investors, RLAY is a Nasdaq-listed United States biotech story with meaningful upside tied to pipeline execution, but also substantial clinical and regulatory risk, as is typical for a company still in the development stage.